Incyte (INCY) News Today $72.05 +0.67 (+0.94%) Closing price 03:59 PM EasternExtended Trading$72.09 +0.04 (+0.05%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Incyte and Genesis collaborate on small-molecule medicinesFebruary 21 at 6:49 PM | msn.comIncyte Q4 Earnings TranscriptFebruary 21 at 7:19 AM | marketbeat.comHussman Strategic Advisors Inc. Makes New $2.90 Million Investment in Incyte Co. (NASDAQ:INCY)Hussman Strategic Advisors Inc. bought a new position in Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 42,000 shares of the biopharmaceutical company's stock, valued at approximatelyFebruary 21 at 6:37 AM | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Purchased by Ieq Capital LLCIeq Capital LLC grew its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 1,342.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 138,536 shares of the biopharmaceutical company'sFebruary 21 at 4:44 AM | marketbeat.comBryn Mawr Capital Management LLC Purchases 13,911 Shares of Incyte Co. (NASDAQ:INCY)Bryn Mawr Capital Management LLC raised its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 262.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,209 shares of the biopharmaceutical company's stock after purchaFebruary 21 at 4:44 AM | marketbeat.comRhumbline Advisers Has $21.15 Million Position in Incyte Co. (NASDAQ:INCY)Rhumbline Advisers lessened its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,206 shares of the biopharmaceutical company's stoFebruary 21 at 3:32 AM | marketbeat.comIncyte: Genesis Therapeutics to receive $30M upfront in AI collaborationFebruary 20 at 2:12 PM | markets.businessinsider.comIncyte and Genesis Therapeutics Announce Strategic AI-focused Research CollaborationFebruary 20 at 8:00 AM | businesswire.comIncyte Co. (NASDAQ:INCY) Short Interest UpdateIncyte Co. (NASDAQ:INCY - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 5,790,000 shares, an increase of 14.9% from the January 15th total of 5,040,000 shares. Approximately 3.1% of the shares of the stock are sold short. Based on an average daily volume of 1,980,000 shares, the days-to-cover ratio is presently 2.9 days.February 18 at 11:03 PM | marketbeat.comIncyte Sees Relative Strength Rating Rise To 71February 18 at 4:43 PM | msn.comAre Wall Street Analysts Bullish on Incyte Stock?February 18 at 5:35 AM | msn.comAllspring Global Investments Holdings LLC Sells 314,500 Shares of Incyte Co. (NASDAQ:INCY)Allspring Global Investments Holdings LLC trimmed its position in Incyte Co. (NASDAQ:INCY - Free Report) by 63.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,997 shares of the biopharmaceuticaFebruary 18 at 3:26 AM | marketbeat.comVan ECK Associates Corp Buys 52,018 Shares of Incyte Co. (NASDAQ:INCY)Van ECK Associates Corp raised its position in Incyte Co. (NASDAQ:INCY - Free Report) by 38.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 186,899 shares of the biopharmaceutical company's stock after buying an additional 52,018 shares during theFebruary 16, 2025 | marketbeat.comWilliam Blair Comments on Incyte's Q1 Earnings (NASDAQ:INCY)February 14, 2025 | americanbankingnews.comIncyte stock price target raised to $88 at TD CowenFebruary 13, 2025 | msn.comIncyte jumps amid takeover speculationFebruary 13, 2025 | msn.comQ1 Earnings Forecast for Incyte Issued By William BlairIncyte Co. (NASDAQ:INCY - Free Report) - Research analysts at William Blair issued their Q1 2025 EPS estimates for Incyte in a report released on Monday, February 10th. William Blair analyst M. Phipps expects that the biopharmaceutical company will post earnings of $0.66 per share for the quarterFebruary 13, 2025 | marketbeat.comState of Alaska Department of Revenue Sells 15,825 Shares of Incyte Co. (NASDAQ:INCY)State of Alaska Department of Revenue reduced its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 46.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,234 shares of the biopharmaceutical companyFebruary 13, 2025 | marketbeat.comIncyte price target raised to $88 from $86 at TD CowenFebruary 12, 2025 | markets.businessinsider.comIncyte price target lowered to $68 from $70 at RBC CapitalFebruary 12, 2025 | markets.businessinsider.comIncyte Stock Sinks as Sales Forecast for Key Drugs Falls ShortFebruary 12, 2025 | msn.comReevaluating Incyte Corporation After Earnings (Technical Analysis)February 12, 2025 | seekingalpha.comIncyte Co. (NASDAQ:INCY) Stock Holdings Lifted by Savant Capital LLCSavant Capital LLC lifted its position in Incyte Co. (NASDAQ:INCY - Free Report) by 304.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,792 shares of the biopharmaceutical company's stock after acquiring an additional 39,7February 12, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 36,357 Shares of Incyte Co. (NASDAQ:INCY)Sumitomo Mitsui Trust Group Inc. lessened its position in Incyte Co. (NASDAQ:INCY - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 447,342 shares of the biopharmaceutical company'sFebruary 12, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Lowered to Buy Rating by StockNews.comStockNews.com cut shares of Incyte from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.February 12, 2025 | marketbeat.comTruist Financial Sticks to Its Hold Rating for Incyte (INCY)February 11, 2025 | markets.businessinsider.comIncyte’s Earnings Call: Robust Growth Amid ChallengesFebruary 11, 2025 | tipranks.comIncyte's (INCY) "Market Perform" Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Incyte in a report on Tuesday.February 11, 2025 | marketbeat.comIncyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | insidermonkey.comRoyal Bank of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock PriceRoyal Bank of Canada decreased their price objective on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating for the company in a report on Tuesday.February 11, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Price Target Lowered to $88.00 at CitigroupCitigroup cut their target price on Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a research report on Tuesday.February 11, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Price Target Raised to $77.00 at Stifel NicolausStifel Nicolaus raised their price target on shares of Incyte from $75.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday.February 11, 2025 | marketbeat.comIncyte: Q4 Earnings Outlines Multiple Drug Launches In 2025February 11, 2025 | seekingalpha.comIncyte: Q4 Earnings Outlines Multiple Drug Launches In 2025February 11, 2025 | seekingalpha.comIncyte’s Stock Under Pressure Amid Phase III Data Uncertainty and Conservative 2025 OutlookFebruary 11, 2025 | tipranks.comCambiar Investors LLC Cuts Stock Holdings in Incyte Co. (NASDAQ:INCY)Cambiar Investors LLC decreased its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 11.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 139,652 shares of the biopharmaceutical company's stock after selling 17,651 shares during the periodFebruary 11, 2025 | marketbeat.comIncyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic OutlookFebruary 11, 2025 | gurufocus.comIncyte (NASDAQ:INCY) Stock Price Down 8.5% Following Weak EarningsFebruary 11, 2025 | americanbankingnews.comDecoding Incyte Corp (INCY): A Strategic SWOT InsightFebruary 11, 2025 | gurufocus.comQ4 2024 Incyte Corp Earnings Call TranscriptFebruary 11, 2025 | gurufocus.comIncyte stock falls 6% amid Q4 earnings, 2025 forecastFebruary 10, 2025 | seekingalpha.comIncyte outlines 2025 milestones with projected $1B in incremental revenue contributionsFebruary 10, 2025 | msn.comIncyte forecasts downbeat annual sales of skin disease drug, shares fallFebruary 10, 2025 | msn.comIncyte stock falls 6% amid Q4 earnings, 2025 forecastFebruary 10, 2025 | seekingalpha.comIncyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4February 10, 2025 | finance.yahoo.comIncyte Corporation (INCY) Q4 2024 Earnings Call TranscriptFebruary 10, 2025 | seekingalpha.comIncyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 LaunchesFebruary 10, 2025 | benzinga.comIncyte (NASDAQ:INCY) Trading Down 8.5% Following Weak EarningsIncyte (NASDAQ:INCY) Shares Down 8.5% After Earnings MissFebruary 10, 2025 | marketbeat.comIncyte reports quarterly sales above estimates on strong demand for key drugsFebruary 10, 2025 | reuters.comIncyte Corporation 2024 Q4 - Results - Earnings Call PresentationFebruary 10, 2025 | seekingalpha.com Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.930.60▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼1312▲INCY Articles Average Week Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Neurocrine Biosciences News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts